Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics riskScore

Myriad Genetics has launched riskScore, which employs a proprietary algorithm combining analysis of 80 SNPs and patients' personal and family history of cancer to determine a woman's risk of breast cancer. Results from this test will be reported alongside Myriad's myRisk Hereditary Cancer test, a 28-gene panel that gauges patients' risk for for eight cancers. RiskScore will help guide decisions for asymptomatic patients who get negative myRisk results, providing definitive answers to the 90 percent of patients testing negative for hereditary cancer genes, the company noted. Myriad has completed two validation studies in patients of European descent that it will present at upcoming conferences.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more